Search results for "TAGL"

showing 10 items of 296 documents

Analysis of early biochemical markers and regulation by tin protoporphyrin IX in a model of spontaneous osteoarthritis

2011

Abstract Age-related changes in joint tissues lead to osteoarthritis (OA). Detection of early changes in OA patients may help to initiate treatments before the establishment of irreversible joint destruction. STR/ort mice develop with age a severe degenerative joint disease that resembles human OA thus allowing the investigation of biochemical markers as well as new treatments in an accelerated time frame. We have analyzed the changes in serum levels of different mediators during the early phases of idiopathic OA in STR/ort mice. Serum levels of matrix metalloproteinase-3 (MMP-3) but not those of tumor necrosis factor-α, interleukin(IL)-1β, IL-17 or prostaglandin E 2 correlated with histopa…

MaleAgingmedicine.medical_specialtyPathologyMetalloporphyrinsmedicine.medical_treatmentDrug Evaluation PreclinicalProtoporphyrinsMice Inbred StrainsOsteoarthritisMatrix metalloproteinaseBiochemistryMiceEndocrinologyInternal medicineOsteoarthritisGeneticsmedicineAnimalsEnzyme InhibitorsMolecular BiologyBiochemical markersbusiness.industryInterleukinCell BiologyClinical Enzyme TestsTin protoporphyrin IXmedicine.diseaseArthritis ExperimentalEarly DiagnosisEndocrinologyHeme Oxygenase (Decyclizing)Disease ProgressionBiomarker (medicine)Matrix Metalloproteinase 3Tumor necrosis factor alphaInflammation MediatorsbusinessBiomarkersProstaglandin EExperimental Gerontology
researchProduct

Conditioned Media from Adipose-Tissue-Derived Mesenchymal Stem Cells Downregulate Degradative Mediators Induced by Interleukin-1β in Osteoarthritic C…

2013

Osteoarthritis (OA) is the most frequent joint disorder and an important cause of disability. Recent studies have shown the potential of adipose-tissue-derived mesenchymal stem cells (AD-MSC) for cartilage repair. We have investigated whether conditioned medium from AD-MSC (CM) may regulate in OA chondrocytes a number of key mediators involved in cartilage degeneration. CM enhanced type II collagen expression in OA chondrocytes while decreasing matrix metalloproteinase (MMP) activity in cell supernatants as well as the levels of MMP-3 and MMP-13 proteins and mRNA in OA chondrocytes stimulated with interleukin- (IL-) 1β. In addition, CM increased IL-10 levels and counteracted the stimulating…

MaleArticle Subjectmedicine.medical_treatmentImmunologyInterleukin-1betaType II collagenAdipose tissueDown-RegulationNitric OxideChondrocytesMatrix Metalloproteinase 13Osteoarthritislcsh:PathologymedicineHumansProstaglandin E2Interleukin 6Collagen Type IICells CulturedAgedbiologyChemistryInterleukin-6Tumor Necrosis Factor-alphaMesenchymal stem cellNF-kappa BInterleukinMesenchymal Stem CellsCell BiologyMiddle AgedCell biologyAdipose TissueCulture Media ConditionedImmunologybiology.proteinTumor necrosis factor alphaFemaleMatrix Metalloproteinase 3Inflammation Mediatorslcsh:RB1-214Prostaglandin Emedicine.drugResearch Article
researchProduct

Paracrine in vivo inhibitory effects of adipose tissue–derived mesenchymal stromal cells in the early stages of the acute inflammatory response

2015

Abstract Background aims Excessive or unresolved inflammation leads to tissue lesions. Adipose tissue–derived mesenchymal stromal cells (AMSCs) have shown protective effects that may be dependent on the modulation of inflammation by secreted factors. Methods We used the zymosan-induced mouse air pouch model at two time points (4 h and 18 h) to evaluate the in vivo effects of AMSCs and their conditioned medium (CM) on key steps of the early inflammatory response. We assessed the effects of AMSCs and CM on leukocyte migration and myeloperoxidase activity. The levels of chemokines, cytokines and eicosanoids in exudates were measured by use of enzyme-linked immunoassay or radio-immunoassay. In …

MaleCancer ResearchChemokineLeukocyte migrationLeukotriene B4medicine.medical_treatmentInterleukin-1betaImmunologyFluorescent Antibody TechniqueAdipose tissueEnzyme-Linked Immunosorbent AssayInflammationMesenchymal Stem Cell TransplantationLeukotriene B4DinoprostoneMiceParacrine signallingchemistry.chemical_compoundCell MovementParacrine CommunicationLeukocytesmedicineAnimalsImmunology and AllergyGenetics (clinical)Prostaglandin-E SynthasesInflammationTransplantationbiologyInterleukin-6Tumor Necrosis Factor-alphaTranscription Factor RelAZymosanMesenchymal Stem CellsCell BiologyIntramolecular OxidoreductasesAdipose TissueOncologychemistryCyclooxygenase 2Culture Media ConditionedImmunologyCancer researchbiology.proteinCytokinesTumor necrosis factor alphamedicine.symptomProstaglandin ECytotherapy
researchProduct

Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.

2019

ObjectivesBimatoprost–timolol (bimatoprost 0.03%–timolol 0.5% fixed-dose combination [FDC]) and tafluprost–timolol (tafluprost 0.0015%–timolol 0.5% FDC) eye drops are currently the only topical intraocular pressure (IOP)-reducing therapies available as preservative-free (PF) prostaglandin and timolol FDC. The aim of this study was to investigate changes to ocular signs and symptoms when patients with ocular hypertension (OH) or open-angle glaucoma (OAG) switched from PF or benzalkonium chloride (BAK)-preserved bimatoprost–timolol to PF tafluprost–timolol eye drops.DesignThis was a 12-week, open-label, phase IV study.SettingSixteen centres in Finland, Germany, Italy and the UK.ParticipantsPa…

MaleIntraocular pressuregenetic structuresOcular hypertensionGlaucomaTimololBenzalkonium chloride0302 clinical medicine1506clinical pharmacology; clinical trials; glaucoma; intraocular pressure; medical ophthalmology; ocular surface; Medicine (all)Aged 80 and overintegumentary systemMedicine (all)General MedicineMiddle AgedIntention to Treat AnalysisDrug Combinations030220 oncology & carcinogenesisTimololFemaleGlaucoma Open-Anglemedicine.drug1718Adultmedicine.medical_specialtyDrug Administration Schedule03 medical and health sciencesOphthalmologymedicineHumansAntihypertensive AgentsIntraocular PressureAgedclinical trialsocular surfaceBimatoprostbusiness.industryResearchPreservatives PharmaceuticalProstaglandins FTafluprostmedicine.diseaseeye diseasesmedical ophthalmologyClinical trialOphthalmologyBimatoprostglaucoma030221 ophthalmology & optometryQuality of LifeOcular Hypertensionsense organsclinical pharmacologyOphthalmic SolutionsbusinessBMJ open
researchProduct

Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.

2010

. Purpose:  The purpose of this study was to investigate the tolerability and intraocular pressure (IOP) reducing effect of the first preservative-free prostaglandin tafluprost (Taflotan®) in patients exhibiting ocular surface side-effects during latanoprost (Xalatan®) treatment. Methods:  A total of 158 patients were enrolled in this open-label multicentre study. Eligible patients had to have at least two ocular symptoms, or one sign and one symptom, during treatment with latanoprost. At baseline, the patients were directly switched from latanoprost to preservative-free tafluprost for 12 weeks. The patients were queried for ocular symptoms, and ocular signs were assessed by using tear brea…

MaleIntraocular pressuregenetic structuresmedicine.medical_treatmentAdministration TopicalMucin 5ACmedicine.disease_causeExfoliation SyndromeConjunctival Diseaseschemistry.chemical_compoundSurveys and QuestionnairesMedicineLatanoprostAged 80 and overBlepharitisGeneral MedicineMiddle AgedTolerabilityPatient SatisfactionAnesthesiaProstaglandins F SyntheticLatanoprostFemalemedicine.symptomIrritationBenzalkonium CompoundsGlaucoma Open-Anglemedicine.drugAdultGonioscopyHyperemiaTonometry OcularHumansBlepharitisAntihypertensive AgentsIntraocular PressureAgedGlaucoma medicationbusiness.industryPreservatives PharmaceuticalProstaglandins FTafluprostHLA-DR Antigensmedicine.diseaseeye diseasesOphthalmoscopyOphthalmologychemistryQuality of LifeItchingOcular Hypertensionsense organsbusinessActa ophthalmologica
researchProduct

Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: Possible role in…

2005

im: To investigate the association of cyclooxygenase-2 (COX-2) expression with angiogenesis and the number and type of inflammatory cells (macrophages/Kupffer cells; mast cells) within primary hepatocellular carcinoma (HCC) tissues and adjacent non-tumorous (NT) tissues. Methods: Immunohistochemistry for COX-2, CD34, CD68 and mast cell tryptase (MCT) was performed on 14 well-characterized series of liver-cirrhosis-associated HCC patients. COX-2 expression and the number of inflammatory cells in tumor lesions and surrounding liver tissues of each specimen were compared. Moreover, COX-2, CD34 staining and the number of inflammatory cells in areas with different histological degrees within eac…

MaleLiver CancerPathologymedicine.medical_specialtyCarcinoma HepatocellularEndotheliumMacrophageAngiogenesisKupffer CellsNeovascularizationCarcinomamedicineHumansMast CellsHCCAgedInflammationbiologyNeovascularization Pathologicbusiness.industryMacrophagesLiver NeoplasmsGastroenterologyMembrane ProteinsGeneral MedicineCOX-2Middle Agedmedicine.diseasedigestive system diseasesAngiogenesimedicine.anatomical_structureMembrane proteinCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesHepatocellular carcinomabiology.proteinTumor promotionFemaleCyclooxygenaseEndothelium Vascularmedicine.symptombusiness
researchProduct

Dietary polyunsaturated fatty acids reduce retinal stress induced by an elevation of intraocular pressure in rats.

2011

International audience; N-6 and n-3 polyunsaturated fatty acids (PUFAs) have been shown to prevent tissue release of inflammatory molecules. We have shown that a combination of n-6 and n-3 PUFAs is more efficient than single supplementations on the long-term consequences of intraocular pressure elevation. We hypothesized that such an association is also more effective during early retinal stress by modifying retinal proinflammatory prostaglandin and cytokine productions. Rats were supplemented for 3 months with n-6 PUFAs, n-3 PUFAs, or both n-6 and n-3 PUFAs. After 3 months, a surgical elevation of intraocular pressure was induced. Retinal morphometry and glial cell activation were evaluate…

MaleMESH : RNA MessengerMESH: Eicosapentaenoic AcidEndocrinology Diabetes and Metabolismmedicine.medical_treatment[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionInterleukin-1betaMESH: Dietary SupplementsMESH: Rats Sprague-DawleyRats Sprague-Dawleychemistry.chemical_compound0302 clinical medicineEndocrinologyMESH: Interleukin-1betaratMESH: AnimalsProstaglandin E2Prostaglandin E1MESH : Tumor Necrosis Factor-alphaMESH : Intraocular Pressure0303 health sciencesNutrition and DieteticsMESH : RatsMESH : NeurogliaMESH: RetinaMESH: Dinoprostonepression intraoculaireMESH: AlprostadilMESH: Docosahexaenoic AcidsBiochemistryEicosapentaenoic AcidDocosahexaenoic acidlipids (amino acids peptides and proteins)MESH: NeurogliaProstaglandin D2Cell activationNeurogliaMESH : Alprostadilmedicine.drugProstaglandin Emedicine.medical_specialtyMESH : DinoprostoneMESH : Interleukin-6Docosahexaenoic AcidsMESH: RatsMESH : MaleProstaglandinBiologyMESH : Interleukin-1betaDinoprostoneRetinaMESH : Diet03 medical and health sciencesMESH: DietMESH: Intraocular PressureInternal medicinemedicineMESH : Eicosapentaenoic AcidAnimalsMESH : Dietary SupplementsRNA MessengerAlprostadilprostanoids030304 developmental biologyMESH: RNA MessengerInterleukin-6Tumor Necrosis Factor-alphadietary polyunsatured fatty acidretinal stressMESH : RetinaRetinalN-6MESH: Interleukin-6MESH : Rats Sprague-Dawleyeye diseasesMESH: MaleMESH : Docosahexaenoic AcidsDietRatsN-3EndocrinologychemistryMESH: Tumor Necrosis Factor-alphaDietary Supplements030221 ophthalmology & optometryMESH : Animalssense organs[SDV.AEN]Life Sciences [q-bio]/Food and Nutritionintraocular pressure
researchProduct

Modulation by opioids and by afferent sensory neurones of prostanoid protection of the rat gastric mucosa.

1992

1. Pretreatment with capsaicin, to deplete sensory neuropeptides from primary afferent neurones or the administration of morphine (9 mg kg-1, i.v.), which can inhibit neuropeptide release, augmented gastric mucosal injury induced by a 5 min challenge with intragastric ethanol in the rat, as assessed by macroscopic and histological evaluation. 2. Morphine administration substantially attenuated the protective actions of the prostaglandin analogue 16,16 dimethyl prostaglandin E2 (dm PGE2; 0.5-20 micrograms kg-1, p.o.) against ethanol-induced damage. This reduced degree of protection by dmPGE2 was not however, the consequence of the enhanced level of damage. 3. These actions of morphine in red…

MaleNarcoticsmedicine.medical_specialtymedicine.drug_classProstaglandinNeuropeptideNalorphine(+)-NaloxoneDinoprostonechemistry.chemical_compoundInternal medicinemedicineAnimalsNeurons AfferentProstaglandin E2PharmacologyEthanolMorphinebusiness.industryNaloxoneRats Inbred StrainsRatsEndocrinologychemistryCapsaicinGastric MucosaMorphineProstaglandinsProstaglandin analogueCapsaicinbusinessmedicine.drugResearch ArticleBritish journal of pharmacology
researchProduct

Modulatory effect of bolinaquinone, a marine sesquiterpenoid, on acute and chronic inflammatory processes

2002

The marine metabolite bolinaquinone is a novel inhibitor of secretory phospholipase A(2) (sPLA(2)), with a potency on the human synovial enzyme (group II) higher than that of manoalide. This activity on the sPLA(2) was confirmed in vivo in the 8-h zymosan rat air pouch on the secretory enzyme accumulation in the pouch exudate. Additionally, bolinaquinone decreased potently the synthesis and release of leukotriene B(4) (LTB(4)) in calcimycin (A23187)-stimulated human neutrophils as a consequence of the inhibition of 5-lipoxygenase activity, as well as PGE(2) and NO production on zymosan-stimulated mouse peritoneal macrophages. This compound exerted anti-inflammatory effects by topical and or…

MaleNeutrophilsGene ExpressionNitric Oxide Synthase Type IIMarine BiologyPharmacologyBone resorptionMicechemistry.chemical_compoundManoalideIn vivoEdemamedicineAnimalsEdemaHumansRats WistarPharmacologybiologyZymosanMembrane ProteinsArthritis ExperimentalPoriferaRatsCarrageenanIsoenzymesRadiographyNitric oxide synthaseDisease Models AnimalchemistryCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesImmunologyMacrophages Peritonealbiology.proteinMolecular MedicineTumor necrosis factor alphaNitric Oxide Synthasemedicine.symptomSesquiterpenes
researchProduct

A novel cyclo-oxygenase-2 inhibitor modulates catabolic and antiinflammatory mediators in osteoarthritis.

2004

ITB (6-(p-bromophenyl)amino-7-(p-chlorophenyl)indazolo[2',3':1,5]-1,2,4-triazolo[4,3-a]-1,3,5-benzotriazepine) is a novel inhibitor of cyclo-oxygenase-2 (COX-2) with antiinflammatory activity in animal models. In the present study, we investigated the effect of this compound on the production of catabolic or antiinflammatory mediators in osteoarthritis (OA) cartilage. In OA cartilage explants, ITB inhibited the production of prostaglandin E(2) (PGE(2)), tumour necrosis factor-alpha (TNF-alpha) and matrix metalloproteinase-13 (MMP-13) in a concentration-dependent manner, whereas nitrite was partially reduced. On the contrary, ITB increased the production of interleukin (IL)-10 and the expres…

MaleOxygenaseIndazolesmedicine.medical_treatmentAnti-Inflammatory AgentsOsteoarthritisPharmacologyBiochemistryOsteoarthritismedicineHumansCyclooxygenase InhibitorsProstaglandin E2AgedPharmacologyCyclooxygenase 2 InhibitorsChemistryCatabolismCartilageAnti-Inflammatory Agents Non-SteroidalInterleukinMembrane ProteinsAzepinesTriazolesmedicine.diseaseIsoenzymesInterleukin 10Cytokinemedicine.anatomical_structureCartilageBiochemistryCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesFemalemedicine.drugBiochemical pharmacology
researchProduct